TLR9 and neoplasm: CpG oligodeoxynucleotides (ODNs) represent a promising class of immunotherapeutic agents that activate the innate immune system through the Toll-like receptor 9 (TLR9) signaling pathway and exert anti-tumor effects by reversing the immunosuppressive tumor microenvironment.